DB4 RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES  by Sun, SX et al.
A234 Paris Abstracts
data by education level from the Bureau of Labor Statistics to the WPAI scores. Work 
productivity and indirect social cost were compared across patient sociodemographic 
characteristics and disease severity. RESULTS: A total of 191 MS patients were evalu-
ated at baseline with 114 working either full-time (78.1%) or part-time (21.9%). In 
this working sample, 75.4% were females, 72.8% were married, 71.1% were below 
50 years old and a majority were White (88.5%). The overall productivity loss due 
to MS among full-time employed patients and part-time employed patients was 42.5% 
(SD: 26.9) and 42.1% (SD: 30.6), respectively. This translates into a substantial pro-
ductivity loss of 17 hours of loss time in a 40-hour work-week for full-time workers 
and 8.4 hours of loss time in a 20-hour work week for part-time workers. At average 
wages, this productivity loss equates to an indirect annual social loss of $18,106 per 
patient (SD: $13,265) among full-time workers and $8,871 per patient (SD: $7,080) 
among part-time workers. Indirect social costs were signiﬁcantly correlated with 
increasing MS severity (r  0.21; p  0.0.029). CONCLUSIONS: Multiple sclerosis 
results in a substantial loss of work productivity among patients, which collectively 
results in signiﬁcant indirect social cost. The MS-related indirect social costs increase 
with increasing MS severity.
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MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS 
FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN 
KOREA
Kang SH, Lee EK
SookMyung Women’s University, Seoul, South Korea
OBJECTIVES: This study compares the result of cost estimation for glaucoma outpa-
tients using micro-costing and gross-costing methods. It also examines the factors 
contributing to the difference in results and investigates the impact of the result by 
costing method on Budget Impact Analysis(BIA). METHODS: Per year costs of glau-
coma outpatients were estimated for micro-costing, which consists of medical fee, eye 
examinations and laser therapy. A decision tree designed with 6 pathways was used. 
A patient’s visit frequency and transition probability for each pathway were obtained 
from literature and clinical expert opinions. In gross-costing, yearly per-capita outpa-
tient average costs were calculated by using health insurance statistics data on glau-
coma (ICD 10 code: H40). For BIA, each costing result was applied to the patients 
nationwide. RESULTS: The calculated costs of annual outpatient were $148.7 and 
$71.1 for micro-costing and gross-costing, respectively. The cost calculated by 
pathway in micro-costing ranged from the minimum of $142.9 to the maximum of 
$589.8. BIA result were $11,302,788 for micro-costing and $5,407,527 for gross-
costing. CONCLUSIONS: One factor contributing to the difference between the two 
methods is the gap between the standard model and the actual use of medical services. 
Another factor particular to gross-costing is that in the case a patient changes medical 
institutions, data from previous institutions do not accumulate, which underestimates 
the total cost of medical care. As a result, different costing methods may result in dif-
ferent decision-making of new drugs.
PODIUM SESSION IV: DIABETES STUDIES
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USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: 
POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH 
AND COMPLICATION RISK ESTIMATES
Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O’Reilly D
McMaster University, Hamilton, ON, Canada
Most previous work estimating survival rates for diabetes has been based on logistic 
regression or standardized ratios to derive odds ratios rather than being based on 
survival analysis with risk estimates over time. Few studies have estimated the excess 
risk between those with and without diabetes. OBJECTIVES: The purpose of this 
study was to estimate the excess risk and cumulative relative risks of death and com-
plications between those with newly diagnosed diabetes and those without. 
METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 and over were 
identiﬁed from the Ontario Diabetes Database and matched 1:2 using propensity 
scores with controls (non-diabetes cases). Using linked provincial administrative data-
bases, data on death and the following complications were recorded: myocardial 
infarction, stroke, angina, heart failure, blindness, amputation, nephropathy and cata-
ract. Kaplan Meier curves were calculated to estimate the probability of being event-
free for those with and without diabetes for up to 10 years of follow-up. RESULTS: 
A total of 610,852 patients aged 35 and over with diabetes were matched with 
1,221,704 patients without diabetes. For those with diabetes vs. those without, there 
was a statistically signiﬁcant increased relative risk at 10 years for death (1.417, [95%] 
CI 1.415–1.418), myocardial infarction (2.094, [95%] CI 2.092–2.095), stroke 
(1.877, [95%] CI 1.874–1.879), angina (1.526, [95%] CI 1.525–1.527), heart failure 
(2.520, [95%] CI 2.529–2.522), amputation (6.824, [95%] CI 6.823–6.824), 
nephropathy (2.902, [95%] CI 2.901–2.904), blindness (1.212, [95%] CI 1.205–
1.218) and cataract (1.326, [95%] CI 1.324–1.327). CONCLUSIONS: Diabetes 
is a signiﬁcant health problem with excess risk of death and complications typically 
associated with diabetes. Using estimates of risk of death or complications for a 
general (non-diseased) population can result in signiﬁcant underestimates of disease 
burden or cost-effectiveness in decision analytic models of disease management or 
prevention.
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OBJECTIVES: To assess the persistence of type-2 diabetic patients treated with basal 
supported oral therapy (BOT) with insulin glargine (GLA) compared to NPH insulin 
(NPH). METHODS: We performed a retrospective cohort study using claims data for 
ambulatory prescriptions within the German statutory health-insurance scheme, based 
on a representative sample of more than 80 % of German community pharmacies. 
Insulin-naive patients treated with oral antidiabetic drugs (OAD) who were addition-
ally initiating therapy with GLA or NPH between January 2003 and December 2006 
were included and followed up until December 2007. Persistence was deﬁned as the 
duration of time from initiation of GLA or NPH until switching to intensiﬁed con-
ventional insulin therapy (ICT). A switch to ICT was assumed whenever a short-acting 
insulin was prescribed for the ﬁrst time followed by at least one prescription of a 
long-acting insulin within six months. Univariate and multivariate Cox proportional 
hazards models were used to compare both cohorts. RESULTS: In total, 97,998 
patients (61,070 Glargine and 36,928 NPH) were included. Within the observation 
period, 23.5 % of GLA patients and 28.0 % of NPH patients switched to ICT. On 
average, these patients stayed 388 days on GLA and 313 days on NPH, respectively 
(p  0.001, log-rank test). The risk of switching to ICT was signiﬁcantly higher for 
NPH patients compared to GLA patients (unadjusted hazard ratio [HR] 1.34 (99 % 
CI: 1.29–1.38)). After adjustment for predeﬁned covariables i.e., type of physician 
(general practitioner vs. specialist), region, insurance status (member, family member, 
retired), health insurance company, comedication, number of OAD, dose of basal 
insulin, the risk for NPH patients remained signiﬁcantly higher (adjusted HR: 1.22 
(99 % CI: 1.18–1.27). CONCLUSIONS: Type 2 diabetic patients under basal sup-
ported oral therapy treated with insulin glargine stay signiﬁcantly longer on initial 
therapy until they switch to ICT when compared to NPH.
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OBJECTIVES: To assess the prevalence of potentially undiagnosed diabetes mellitus 
(UDM) in a nationally representative patient sample. METHODS: The data source 
was GE’s Medical Quality Improvement Consortium (MQIC) database (February 
2009) containing electronic medical record (EMR) data on 11 million patients in the 
U.S. Two previously published (Holt, et al, 2008) search strategies were applied to 
identify patients without diagnosis or medication evidence of DM, but with a fasting 
(FBG) or random blood glucose (RBG) result available (denominator for prevalence 
estimates). Strategy A patients were non-DM patients whose last glucose on record 
(LGOR)  RBG q11.1 or FBG q7.0 mmol/l. Strategy B patients were non-DM 
patients with LGOR (FBG or RBG) q7.0 mmol/l. Strategy A and B patients were each 
grouped by age/sex categories, and prevalence of UDM calculated. The time since 
LGOR to datacut date was also assessed. RESULTS: From 11,196,881 total patients, 
923,007 had diagnosed DM on record (n  570,723) or were presumed to have DM 
on the basis of prescribed oral hypoglycemics or insulin (n  352,284). After exclud-
ing additional patients with gestational diabetes and impaired glucose tolerance/pre-
diabetes,10,147,355 remained. Of these, 3,799,599 had a glucose result available, 
with 38,068 identiﬁed as possible UDM using Strategy A (prevalence 0.38%), and 
221,624 using Strategy B (prevalence 2.18%). In both instances, UDM prevalence 
increased with increasing age, in both sexes. Over 2 years had elapsed since the 
LGOR for over 50% of Strategy A patients, and 40% of Strategy B patients. 
CONCLUSIONS: The application of simple search algorithms to a large EMR data-
base suggests there may be substantial underdiagnosis of DM in the US general 
population.
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OBJECTIVES: To evaluate the risk of stroke or myocardial infarction (MI) in patients 
with type-2 diabetes mellitus (T2DM) receiving pioglitazone (PIO) or non-thiazolidin-
edione (Non-TZD) therapies. METHODS: A analysis of I3 Innovus database from 
January 1, 2000 to June 30, 2007 was conducted. T2DM patients (ICD-9 diagnosis 
codes 250.x0 or 250.x2) were grouped into PIO or Non-TZD cohorts based on the 
study drugs initiated. The index date is the ﬁrst dispensing of pioglitazone or Non-
TZD medications. Follow-up started at the index date and ended upon disenrollment 
from the health plan, ﬁrst occurrence of stroke or MI, or the end of the period, 
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whichever came ﬁrst. Patients were excluded if they had type-1 diabetes or were pre-
scribed rosiglitazone or troglitazone during the study period, or had stroke, MI, or 
brain injury prior to index date. Cox proportional hazards model was used to estimate 
risk for stroke or MI controlling for demographics, baseline comorbidities, medication 
use and resource utilization. RESULTS: A total of 85,253 patients with T2DM were 
included; total of 9053 (10.62%) patients were on PIO and 76,200 on Non-TZD 
cohort; a total of 178 (1.97%) patients who initiated PIO were hospitalized for stroke 
or MI compared to 1838 (2.41%) patients in the Non-TZD cohort (P  0.001) during 
the follow-up period. The unadjusted incidence ratio for stroke or MI hospitalization 
associated with PIO relative to Non-TZD was 0.789 (95% CI: 0.677–0.921). After 
adjusting for baseline covariates in the multivariate analysis PIO patients were less 
likely to have stroke or MI hospitalization than Non-TZD patients, adjusted hazard 
ratio was 0.854 (95% CI: 0.732–0.997). CONCLUSIONS: T2DM patients initiated 
on pioglitazone were at reduced risk of having stroke or MI hospitalization than 
Non-TZD patients during the follow-up period. The result is consistent with clinical 
trial metaanalyses demonstrating lower risk of stroke or MI with pioglitazone com-
pared to other oral antidiabetic agents.
PODIUM SESSION IV: MODELING METHODS – HANDLING 
UNCERTAINTY
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Trials powered to show signiﬁcant differences in a combined end-point invariably 
lack power when considering the individual end-points. Analyzing them individually 
leads to wide uncertainty margins which may have important consequences, especially 
when death is included. OBJECTIVES: To develop methods which recognize the 
process underlying the occurrence of endpoints and to analyze whether such methods 
lead to different point estimates and different results in probabilistic sensitivity analy-
ses (PSA). METHODS: Two methods are compared with the “usual” approach, where 
individual events are modeled as the outcomes of a multinomial distribution. The 
ﬁrst method heroically assumes that the risk reduction of the combined endpoints 
can be applied to the total event rate after which a partial multinomial model can 
be used for the events. The second method uses a Bayesian meta-regression which 
is programmed in Winbugs and includes data from earlier trials in the same area 
with and without the inclusion of explanatory variables. The two methods are illus-
trated using MI/stroke free survival as an endpoint from studies concerning lipid 
lowering therapy and studies concerning platelet inhibition. In the ﬁrst, lipid levels 
are included as explanatory variables, in the second an unobserved common process 
is assumed. RESULTS: Analysis of data from six cholesterol trials and ﬁve platelet 
studies shows that assuming that the risk reduction applies to all events reduces 
the uncertainty by between 12–22% without affecting the point estimates. When 
using the Bayesian meta-regression models, the uncertainty is decreased by between 
30%80% with explanatory variables and between 16–45% without explanatory 
variables. However, point estimates may change more substantially as guided by the 
evidence from prior observations. CONCLUSIONS: Using Bayesian meta-regression 
to capture the dependence between endpoints in a combined endpoint-study may 
reduce the uncertainty of PSA results substantially. The magnitude of the reduction 
seems greater than when making heroic assumptions concerning the underlying 
dependence.
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EARLY MODELLING: METHODS IN THE ECONOMIC ANALYSIS OF  
PRE-PHASE II PRODUCTS
Taylor MJ, Saxby R
University of York, York, UK
OBJECTIVES: Economic evaluations are increasingly used as tools to inform 
decision-makers about the cost-effectiveness of health technologies. Such evaluations 
are often undertaken during the late stages of the technology development (i.e. 
around the time of product launch or, in some cases, post-launch). However, there 
is an increasing need for the manufacturers of the technology to appraise the 
likely cost-effectiveness of the intervention before making decisions on price and 
indication, as well as to inform the development of clinical trials. METHODS: Due 
to the simpliﬁed nature of such ‘early analyses’, there is no availability of Phase III 
trial data, or evidence of subtle interactions between parameters. The purposes of 
such an analysis are to allow the user to determine the relative importance of 
different parameter inputs, in order to inform decisions on pricing, target populations 
and further research. This presentation outlines the key advantages and limitations 
of early modelling, and how the decision maker should interpret such analyses. 
RESULTS: This study demonstrates that early modelling is a vital exercise even 
(and, sometime, especially) when there is a signiﬁcant lack of cost and effectiveness 
data. Early models can be an effective tool for determining price and target indications. 
A variety of outputs are demonstrated that will maximise the usefulness of such models 
to the decision maker. CONCLUSIONS: Even when there is a lack of Phase III data, 
economic models are a useful tool. However, the approach to modelling in such 
circumstances is signiﬁcantly different to that when ‘full’ models are prepared. This 
study demonstrates how the value of early models can be increased, using a number 
of key outputs.
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Value of information (VOI) is a monetary measure of the impact of uncertainty on a 
decision, quantiﬁed in terms of the expected value of perfect information. When 
uncertainty in control parameters is high, new information will carry high value in 
improving the value of a decision. Conversely, if parameters are known precisely, new 
information would not be considered valuable. VOI analysis is intuitively appealing, 
aims to improve our interpretation of the ﬁndings of health economic evaluations, and 
help plan further work—indeed, it is being declared mandatory in some jurisdictions. 
The implications of inaccurate or incomplete VOI analyses is potentially great, 
however; overestimating VOI leads to wasted funds on unnecessary research and 
delays in getting new treatments to markets, while underestimation exaggerates the 
strength of a possibly false decision. In this research, we provide a conceptual overview 
of VOI and discuss some of the key challenges involved in its proper use, with particu-
lar focus on the elements that are not being discussed: components that may bear the 
largest uncertainty such as the structure of the underlying model, the choice of model-
ing technique and the way in which the core control parameters are formulated and 
estimated.
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Meta-models could reduce simulation time when running probabilistic sensitivity 
analyses (PSA) in complex cost-effectiveness analyses models. OBJECTIVES: To 
compare approximations of PSA outcomes by Ordinary Least Squares (OLS), Spatial 
Interpolation (SI) and Gaussian Process (GP) in terms of accuracy and computation 
time using a simple example. METHODS: Three meta-models are used to ﬁt the 
relationship between inputs and outputs considering a cost-effectiveness model 
addressing cardiovascular treatment and using a selection of well chosen combinations 
of inputs. Using separate models for both incremental costs and incremental effects, 
and varying the number of design-points, accuracy is measured by comparing the Root 
Mean Squared Error (RMSE), as comparing thousand out-of-sample predictions of 
the meta-models with the corresponding outputs of the cost-effectiveness model. 
Computation time was deﬁned as programming and running time. The Gaussian 
Process emulator is used in combination with regression. RESULTS: The PSA results 
of the cost-effectiveness model were not linear (RESET test) in both costs and effects 
but the linear model showed relatively high R-squares (0.7 and 0.85). Based on RMSE, 
the GP gives the best results, followed closely by SI. OLS has the smallest computation 
time, followed by GP and SI. Latter difference mostly explained by difference in pro-
gramming time. The fewer design points for the meta-models, the smaller the gap 
between OLS and the interpolation-based models. CONCLUSIONS: GP/SI had best 
accuracy but needed most computation time, while OLS is quickest but the least 
accurate. The difference in accuracy between SI and GP is explained by the non-
 linearity of the relationship. The superiority of GP over SI decreases with increasing 
numbers of design points.
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TRANSLATION AND LINGUISTIC VALIDATION: EVIDENCE TO 
SUGGEST THAT AN IN-COUNTRY REVIEW IS NECESSARY
Gergovich KB, Houchin C, Wild D
Oxford Outcomes Ltd, Oxford, UK
OBJECTIVES: The use of in-country reviews in the translation process of PRO mea-
sures is an important process. It allows for an existing language version to be modiﬁed 
for use in another country where the same language is spoken. The following lan-
guages are examples of where this can apply: English, Portuguese, Spanish, Chinese, 
Arabic, Russian and French. If a translation completed for one country is not reviewed 
for use in another, there is a risk that the translation may not be linguistically or cul-
turally valid in the new country. This study sets out to outline the level of changes 
made when carrying out this process. METHODS: A sample of in-country reviews 
was taken from the translation of the POLO Chart measure. A total of 9 languages 
were reviewed. All changes that were made to any of the translations as a result of 
the in-country review were assessed according to whether the change was made as a 
result of a deﬁnitive linguistic and/or cultural difference (in the opinion of the in-
country reviewer) or whether the change was made based on subjective preferences 
on behalf of the reviewer. RESULTS: A total of 213 changes were made across the 
9 languages. The majority (140) of changes made were considered to be essential 
changes which were as a result of linguistic and/or cultural differences between the 
countries. More changes were made to the Chinese, Portuguese, and Spanish transla-
tions than to the English. CONCLUSIONS: In-country reviews are very useful in the 
translation process of PRO measures. A large number of changes made across the 9 
languages and the fact that the majority of changes made to the translations are con-
sidered to be essential based on linguistic and/or cultural differences suggest that the 
in-country review is an important process to undertake.
